surpass cvot tirzepatide results Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT | Diabetes Therapy SURPASS-CVOT Published: Large Trial Confirms

Gastrointestinal Disorders: Ileus -Ozempic warning label, as of April 2024 The warning label still doesn't mention the potential harms of ileus, like blockages and obstruction

TIRZEPITIDE Tirzepatide is a once-weekly injectable medication designed to treat type 2 diabetes and support weight management

Apply gentle pressure with clean gauze if bleeding occurs, but avoid rubbing the area

Remember, every journey has its challenges, but with the right strategies and support, you can overcome them and enjoy the benefits of a healthier, happier you

Diabetologia 62 , 316 (2019) R

If it is frozen, ice crystals can form and damage the structure of the drug, which can make it cloudy and ineffective once thawed